Diana Hausman

This profile gathers the share dealings of Diana Hausman across 3 companies, led by Zymeworks Inc., Zentalis Pharmaceuticals, Inc. and Immuneering Corp. The record holds 22 filings, for trades running from 8 January 2019 to 2 July 2025.

On the open market, the record shows 1 purchase worth €7,618 and 5 sales worth €2.7M. On balance, insiders were net sellers of €2.7M. Unlike grants, an open-market purchase is paid for by the insider, at the market price. The rest of the record consists of 6 share grants and 10 option exercises. Since January 2025: 1 purchase and no sales on the market.

The latest filing, published on 7 July 2025, reports an open-market purchase of €7,618 in Immuneering Corp. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 2 days. US insiders must file a Form 4 within two business days of a trade. Sales are harder to read than purchases, since they often meet personal needs such as tax or diversification. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.